Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price decreased by Morgan Stanley from $83.00 to $79.00 in a report released on Friday morning, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock.
Several other equities analysts have also commented on the stock. ValuEngine raised shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating in a report on Thursday, July 18th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating and set a $73.00 target price on the stock in a report on Tuesday, April 23rd. BidaskClub raised shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a report on Tuesday, July 23rd. Wedbush reaffirmed an outperform rating and set a $75.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday. Finally, Barclays reissued a buy rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, May 9th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $75.93.
Shares of Ultragenyx Pharmaceutical stock traded down $1.20 on Friday, hitting $54.46. 14,198 shares of the company traded hands, compared to its average volume of 440,652. The company’s 50-day simple moving average is $60.73. The company has a current ratio of 11.77, a quick ratio of 11.60 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $3.20 billion, a P/E ratio of -7.33 and a beta of 2.17. Ultragenyx Pharmaceutical has a 12-month low of $37.44 and a 12-month high of $90.98.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 527.49% and a negative return on equity of 52.66%. The company had revenue of $24.15 million for the quarter, compared to analyst estimates of $22.16 million. During the same quarter last year, the firm earned ($1.06) EPS. The firm’s quarterly revenue was up 88.8% compared to the same quarter last year. Research analysts forecast that Ultragenyx Pharmaceutical will post -6.96 EPS for the current year.
In other news, EVP Karah Herdman Parschauer sold 1,226 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $61.50, for a total transaction of $75,399.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.80% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of RARE. Meeder Asset Management Inc. lifted its position in Ultragenyx Pharmaceutical by 321.1% during the 1st quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 456 shares during the period. First Mercantile Trust Co. lifted its position in Ultragenyx Pharmaceutical by 101.0% during the 1st quarter. First Mercantile Trust Co. now owns 985 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 495 shares during the period. Exane Derivatives lifted its position in Ultragenyx Pharmaceutical by 95.7% during the 1st quarter. Exane Derivatives now owns 1,601 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 783 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Ultragenyx Pharmaceutical by 19.7% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,303 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 379 shares during the period. Finally, Fox Run Management L.L.C. purchased a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $204,000.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Read More: Why does a company issue an IPO?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.